A typical ARLE Catalyst engagement runs 6–24 months and moves through three phases — Build, Launch, and Scale — each tied to real clinical and regulatory milestones, not an arbitrary calendar.
The commercial foundation required before market entry. This is where clinical, regulatory, investor, and brand strategy get built together — not bolted on later.
Commercial strategy & roadmap, competitive assessment, messaging & brand identity, digital strategy by audience.
Clinical strategy, regulatory alignment, EOS value assessment & gap identification.
Investor relations strategy & positioning to support fundraising alongside clinical progress.
Physician & patient customer journey mapping, KOL strategy — engagement, advising, coaching, competitive analysis.
Sustaining clinical and market momentum through milestone execution — building the credibility and awareness that a launch depends on.
Clinical marketing & site engagement, scientific communications, medical education.
Conferences & symposia, campaign optimization, digital social listening.
Ongoing investor communications tied to real clinical and regulatory milestones.
Market analytics to scale phase, manufacturing demand forecasting.
Preparing the organization for rapid commercial adoption at scale, from clearance through global expansion.
Commercialization & launch execution, sales enablement.
Market access & VAC toolkits to support reimbursement and hospital purchasing pathways.
Turning clinical evidence and KOL relationships into referral behavior and standard-of-care adoption.
Sequencing international markets once U.S. commercial traction is established.
Most companies are further along in one phase and further behind in another than they think. A short conversation usually clarifies it fast.